Ahoy Captain
I took this off the yahoo thread I had a problem with the link so I went ahead and did the edit/paste instead, hope they don't mind.
------------------------------------------------------------------------
Immune Response Up 20% On Upbeat Interim Drug Trial Review
NEW YORK (Dow Jones)--Shares of Immune Response Corp. (IMNR) rose 23% on heavy volume, a move the company linked to encouraging feedback from a group that reviewed an ongoing study of the HIV therapy Remune in Thailand.
The Data Safety Monitoring Board completed its first interim analysis meeting in Thailand for the 40-week study over the weekend, just prior to Monday's start of a weeklong international conference in Thailand on HIV vaccine development.
According to Creighton Lawhead, vice president of commercial affairs at the Carlsbad, Calif., biopharmaceutical company, the DSMB "reported that the study was going well and that it had a very high probability of successful outcome."
The last participants in the 297-patient trial will be treated in late July and early August, he said.
In the interim, the principal investigator of the study will submit an application to the Thai government for the registration of Remune in Thailand. The country's minister of health has indicated that the drug would be subject to an accelerated approval process because of near-epidemic levels of HIV infection there, Lawhead said.
Last October, Immune Response and Agouron Pharmaceuticals Inc. (AGPH) agreed to collaborate on the development and sale of Remune. "I look at this as yet another step in Remune's acceptability and availability and ultimate approval in the U.S.," said an Agouron spokeswoman.
Immune Response was recently up 1 7/8, or 23.3%, at 9 15/16 on Nasdaq volume of 1 million shares. Average daily volume is 297,000.
-------------------------------------------------------------------------------- |
